AOD-9604 vs HGH Fragment 176-191: Ring-Closed Versus Open-Chain, Compared for the Lab

The two compounds share a sequence but not a chemical state. HGH Fragment 176-191 is simply the final stretch of growth hormone, whereas AOD-9604 adds a tyrosine at the start of the chain and is supplied with both cysteines already linked through a disulfide bond. The molecular weights make this visible: the fragment weighs 1817.12 g/mol and AOD-9604 1815.08 g/mol, and that difference matches the two hydrogens released as the ring closes. Comparing AOD-9604 with the hGH 176-191 fragment is therefore a question of three-dimensional shape and of proving what is in the vial, not of amino-acid sequence.

Both products — AOD-9604 and HGH Fragment 176-191 — are offered as freeze-dried powder in 10 mg and 5 mg vials, each lot accompanied by its own HPLC certificate, and both sit in our fat-loss and metabolic peptide category.

Where the two molecules come from

Mapping work on human growth hormone in the 1980s and 1990s pointed to the C-terminal end as the source of its fat-tissue effects, while the regions responsible for GH-receptor dimerisation and IGF-1 induction were located in other parts of the 191-amino-acid chain. Excising that end segment was a straightforward way to test the idea: if a 16-residue peptide could reproduce adipose readouts without triggering receptor-mediated growth signalling, the two activities would have to be separate domains rather than two sides of a single response.

That excised segment is HGH Fragment 176-191. AOD-9604 is the version that was taken further in development: an extra tyrosine was placed at the N-terminus and the two cysteines were bonded to each other, locking the chain into the loop it forms inside the folded hormone rather than letting it flex freely. Full-length growth hormone is a prescription-only biologic; it appears in our catalogue purely as a reference entry under somatropin and is not supplied as a research reagent.

Everything hinges on the disulfide bond

A short peptide with two cysteines can exist in three practical forms: both thiols free, the two bonded to each other within one molecule, or bonded across molecules to form dimers and higher aggregates. The ring-closed and open versions differ by only 2 Da — easy to miss if a mass spectrum is skimmed instead of properly read — but they can present a different shape to a receptor, aggregate to different extents, and keep differently.

This is why comparing AOD-9604 with the fragment is chiefly a problem for the analyst, not the pharmacologist. Dissolve the fragment at low concentration, let air reach it, and some molecules will close their ring on their own, slowly becoming AOD-9604-like without anyone noticing. It works in the opposite direction too: put AOD-9604 into a reducing environment such as a DTT- or beta-mercaptoethanol-containing buffer and the bond breaks. If neither material's oxidation state is verified when it is actually used, the experiment compares what is printed on two labels, not two defined molecules.

What the literature can and cannot support

Most published data on the pair come from cultured cells and rodents. Fat-cell cultures dominate, typically quantifying glycerol and free fatty acids in the medium as a proxy for lipolysis, plus lipogenic enzyme activity and, in some studies, the contribution of beta-adrenergic pathways. Animal work has tracked the size of fat depots and assorted metabolic parameters. Running through all of it is a comparison with full-length growth hormone: can the fragment act on fat tissue without the reduced insulin sensitivity and raised IGF-1 that the intact hormone brings?

An honest summary needs two qualifications. First, the findings are inconsistent — a number of laboratories saw smaller effects than the early publications, or none — and that variability is one reason both molecules are still classed as research tools. Second, AOD-9604 has been studied in regulated clinical programmes, but those results relate to pharmaceutical-grade material administered under medical oversight; they do not transfer to a research-grade vial and are mentioned here only to describe where the evidence stands.

Which compound suits which research question

Choose AOD-9604 when you need a fixed conformation

If the design depends on a single, repeatable molecular form — binding assays, structure–activity work, or any setup where shape varying between lots would invalidate the data — the cyclised peptide is the more tightly defined material. It is also the logical choice when replicating published AOD-9604 work, because the extra tyrosine and the ring were part of what those studies tested.

Choose the fragment when you need the native sequence

If you want to study the C-terminal region of hGH exactly as it occurs in the full protein, the unaltered fragment is more faithful — nothing added, nothing locked in place. It also suits groups that prefer to control oxidation themselves, for instance by running a deliberately reduced arm next to a deliberately oxidised one.

Choose both when ring closure is what you are testing

The two compounds make a rare, tidy comparison: the same sequence, separated only by one extra residue and one ring closure. Running them in parallel tests directly how much of an observed effect depends on shape rather than on the amino-acid sequence. Labs that look beyond GH fragments often include a mechanistically unrelated metabolic tool — for example 5-Amino-1MQ to separate pathway-specific signals from general fat-cell responses; background on the lipolytic fragment itself is in our separate article.

Reconstitution, storage and handling differences

Both peptides are short and dissolve readily in water, and both are far simpler to work with than acylated incretin analogues — though the fragment, with its unpaired cysteines, needs more care. Store unopened freeze-dried vials of either one in the freezer, and allow them to reach room temperature before you open them so moisture does not condense on the cold powder. Add diluent slowly along the inside of the vial and give the cake time to dissolve; do not shake.

What the fragment specifically requires is limited contact with oxygen. Its free thiols react with air dissolved in the solution, more quickly above neutral pH or when traces of metal are present, so make working solutions on the day, keep them mildly acidic if the assay tolerates it, and do not store them in a tube with a large air gap. AOD-9604, supplied with the ring closed, is much less sensitive, yet it too must stay out of reducing buffers. The concentration arithmetic is identical for both: a 5 mg vial plus 2 mL of diluent gives 2.5 mg/mL, i.e. 2,500 mcg/mL, and 250 mcg is contained in 0.1 mL. Because the molecular weights differ by just 2 g/mol, a mass-based concentration is practically also a molar one for either compound — convenient when running them head to head. The reconstitution and storage guides cover the details; split each stock into aliquots to avoid repeated freeze-thaw.

Purity, identity and certificate checks

With just 2 Da between them and no way for a purity figure to distinguish them, the certificate matters more here than for most peptides. Check the reported mass against the theoretical one — 1815.08 g/mol for AOD-9604 and 1817.12 g/mol for the fragment — and do not accept a bare monoisotopic value if the instrument resolution is not given. On the HPLC trace, look for a second peak of similar height just before or after the main one, which for peptides with cysteines frequently indicates mixed oxidation states, and for a heavy-side shoulder suggesting dimers bonded through disulfides. Make sure the lot number printed on the certificate is the same as the one on your vial. The COA guide lists what a complete certificate should include.

Regulatory position

Both peptides are sold solely as research chemicals for laboratory work; they are not for human consumption. Neither has marketing authorisation as a medicine in the EU or the United States. AOD-9604 has been evaluated in investigational studies and has food-ingredient status in some jurisdictions, but none of that applies to the research reagent offered here. Full-length growth hormone is a prescription-only biologic and appears in our catalogue as a reference entry only. The metabolic research overview gives the wider picture.